Concentra Group Holdings Parent

CON · NYSE

$38.76+$0.58 (+1.52%)TodayMarket closed · Oct 20, 7:57 PM ET

Prev close $38.18

CON analyst rating

BuyConsensus of 8 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy8
Hold0
Underperform0
Sell0

12-month price target · 9 analysts

Average $41.53 (+7.1% upside)

Low: $40.40
Now: $38.76
High: $44.10

Upgrades and downgrades

The latest rating actions, newest first

CON analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Stephens & Co.	Oct 20, 2026	Initiates	Overweight	$45.00	—
Jefferies	Oct 16, 2026	Initiates	Buy	$47.00	80%
JP Morgan	Sep 10, 2026	Maintains	Overweight	$34.00 → $43.00	71%
Wells Fargo	Aug 11, 2026	Maintains	Overweight	$28.00 → $40.00	59%
Truist Securities	Aug 10, 2026	Maintains	Buy	$37.00 → $42.00	67%
RBC Capital	Aug 10, 2026	Maintains	Outperform	$36.00 → $42.00	57%
Truist Securities	Jul 14, 2026	Maintains	Buy	$31.00 → $37.00	67%
William Blair	Jul 1, 2026	Initiates	Outperform	—	100%
Goldman Sachs	Jun 5, 2026	Initiates	Buy	$30.00	64%
Truist Securities	May 11, 2026	Maintains	Buy	$29.00 → $31.00	67%

The case for and against

Updated Oct 14, 2026

Bull case

Concentra Group Holdings is well positioned by its differentiated employer- and workers’ compensation-focused reimbursement mix, with virtually no exposure to traditional government or commercial health plan payment risk. The company is showing strong operating momentum, including 2Q revenue of $606.0M, adjusted EBITDA of $140.9M, free cash flow of $121M, and nearly 3.0x net leverage, while margins expanded on disciplined cost control and higher revenue per visit. Growth is also being reinforced by 27.9% organic growth in onsite health clinics, a robust M&A/de novo pipeline, and early gains tied to manufacturing, construction, and data center activity.

Bear case

Concentra Group Holdings is exposed to several fundamental headwinds that can weaken demand and compress profitability, including lower employment rates that reduce work-related injuries, state fee schedule changes, and regulatory or audit risk. Its outlook is also constrained by execution risk in its development strategy, plus dependence on maintaining relationships with key customers, workers’ comp payors, and a sufficient clinical workforce amid changing labor market dynamics. Even with leading scale and solid secular tailwinds, these risks could undermine growth, complicate acquisition integration, and pressure valuations tied to 2026 and 2027E EBITDA multiples.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.